Press Release Communiqué de presse - April 06, 2021 6 April, 2021

Sernova Announces Presentation at the American Diabetes Association 81st Scientific Sessions

April 6, 2021 9:00 am ET

LONDON, ONTARIO – April 6, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead principal investigator Dr. Piotr Witkowski and the Clinical Trial Investigator Team for its US Phase I/II Type 1 Diabetes clinical trial will present data and observations from the ongoing study in a poster presentation at the upcoming American Diabetes Association’s (ADA) 81st Scientific Sessions to be held June 25 - 29, 2021.

The abstract will also be published online at the journal Diabetes® website and the presentation will be available to conference attendees on Friday, June 25, 2021.

Dr. Witkowski, Director, Pancreatic and Islet Transplant Program at the University of Chicago, is also scheduled to deliver a lecture titled “Islet Transplantation – Benefits and Shortcomings”, as part of the Clinical and Regulatory Hurdles Facing Islet Transplantation session on Monday, June 28, 2021, at 8:00 am ET.

Note: all information contained in the submitted abstract should be considered preliminary and subject to change until the study data and observations are fully presented at the ADA 81st Scientific Sessions and is subject to embargo until June 25, 2021, at 11:30 am ET.

ABOUT SERNOVA’S CELL POUCH SYSTEM The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA CORP. Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells ( i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

ABOUT THE ADA’s SCIENTIFIC SESSIONS The American Diabetes Association’s (ADA) 81st Scientific Sessions, the world’s largest scientific meeting focused on diabetes research, prevention, and care, will be held virtually June 25-29, 2021. Leading physicians, scientists, and health care professionals from around the world will unveil cutting-edge research, treatment recommendations and advances toward a cure for diabetes. Though the conference will be remote this year, attendees will receive exclusive access to nearly 2,000 original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Learn more and register at scientificsessions.diabetes.org and join the Scientific Sessions conversation on social media using #ADA2021.

FOR FURTHER INFORMATION, PLEASE CONTACT: Dominic Gray Sernova Corp. Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - March 15, 2021 15 March, 2021

Sernova Provides Positive Outlook Regarding the Development of Its Innovative Therapeutics Platform Technology for Chronic Diseases

Sernova is the first and only regenerative medicine therapeutics platform company to demonstrate a well- vascularized subcutaneous islet transplant technology achieving persistent islet graft function in diabetic patients

Sernova CEO hosting an investor conference call on March 18, 2021 at 11:00 am (EDT)

March 15, 2021 9:00 a.m. EDT

LONDON, ONTARIO – March 15, 2021 – Sernova Corp. (TSX-V:SVA) (FSE/XETRA:PSH) (OTCQB:SEOVF), a clinical-stage regenerative medicine company, today provides a Corporate Update and highlights recent key achievements in its pipeline, including its diabetes clinical program as well as other leading development programs.

“I am pleased that our clinical study based on our unique technology platform continues to contribute significant advancements to the field of regenerative medicine therapeutics. This is demonstrated by ongoing positive patient outcomes in safety, tolerability, and efficacy measures as we actively approach completion of full study enrolment. These advancements are occurring despite ongoing global uncertainty related to the COVID-19 pandemic. In this restrictive environment, Sernova also achieved significant advancements in our other therapeutic programs and in the development of technologies that we believe are building significant shareholder value and justified optimism for patients suffering from chronic diseases. As validation of our strategic approach, we are pleased with the recently completed institutional led bought deal financing of $23M. We are aggressively moving forward with all of our programs,” said Dr. Philip Toleikis, President and CEO of Sernova.

DIABETES : SERNOVA’S LEAD CLINICAL INDICATION

Sernova’s principal investigator in its US Phase I/II diabetes clinical trial, Dr. Piotr Witkowski, presented an update at the recent 2021 21st Winter Symposium of the American Society of Transplant Surgeons based on data from its current clinical trial: A Safety, Tolerability and Efficacy -Study of Sernova's Cell Pouch for Clinical Islet Transplantation.

Five of the 7 planned patients have been enrolled, implanted with the Cell Pouch, and are advancing through the transplantation phases of the study.

The following key findings to date have been noted in our trial patients:

• The Primary Safety Endpoint of the study continues to be met:

o the Cell Pouch, following implantation under the skin, shows consistent incorporation with vascularized tissue in multiple patients providing a suitable environment for the survival and function of insulin producing cells; and

o the implanted Cell Pouch and therapeutic cells continue to demonstrate a positive safety profile with no serious adverse events related to the Cell Pouch.

• The Secondary Efficacy measures continue to show clinical benefit in the most advanced treated patients including:

o absence of life-threatening hypoglycemic episodes;

o enduring presence of insulin produced by the Cell Pouch transplanted cells (measured by the biomarker C- peptide) in the bloodstream;

o reduction or elimination in the daily amount of insulin injected; and

o a reduction in HbA1c, a measure of long-term blood sugar control, which can lead to reduced diabetic complications.

Pre-screening of the final two patients is actively underway to complete study enrollment.

HEMOPHILIA A

Sernova as a member of the Horizon 2020 HemAcure Consortium (HemAcure Consortium) presented results of the Consortium’s research at the American Society of Gene and Cell Therapy. Importantly, the following highlights were presented:

• hemophilia A patients unable to express the required clotting factor VIII (FVIII) blood cells were isolated;

• the human FVIII gene responsible for the production of the missing required clotting factor was successfully inserted to achieve a therapeutic effect;

• the safety of these newly corrected cells and their ability to produce sufficient human clotting factor both in laboratory and in an initial preclinical animal model was confirmed.

o human FVIII blood levels reached up to 10%, which is considered sufficient to enable patients to regain their clotting ability;

o these corrected therapeutic cells in the Cell Pouch were successfully assessed in a preclinical model of hemophilia A showing long-term survival of cells;

o human FVIII was also detected in the bloodstream long-term (measured up to four months, the length of the study, following treatment); and

• data further confirmed functional clotting improvement in the blood at the four months time point where human FVIII corrected cells transplanted into the hemophilia A preclinical model restored the animals clotting activity to a therapeutic level within the Cell Pouch.

“These results demonstrate the success in developing a novel approach for the treatment of hemophilia A. These results continue to showcase Sernova’s Cell Pouch platform technologies for the treatment of multiple indications including rare diseases where a gene can be inserted into cells to produce any protein or factor required to treat disease,” added Toleikis. “We look forward to completing work to bring this and other novel therapies to human clinical testing as soon as practicable.”

HYPOTHYROID DISEASE

Sernova is developing a treatment for hypothyroid disease following complete or partial removal of the thyroid gland (thyroidectomy). To advance this platform technology, in collaboration with Dr. Sam Wiseman and in part funded by a Transplant Venture Grant awarded by the Transplant Research Foundation (TRF) of British Columbia, we are assessing healthy human thyroid tissue in preparation of a clinical program.

This new treatment approach allows patients to preserve their thyroid function following a thyroidectomy by transplanting healthy thyroid cells into Sernova’s Cell Pouch. Currently completed pre-clinical work is setting the stage for a regulatory submission for this second clinical program.

PLATFORM EXPANDING TECHNOLOGIES AND CORPORATE COLLABORATIONS

Sernova is acquiring and developing state of the art technologies. These involve both unique cell encapsulating technologies and gene editing technologies to reduce or eliminate the need for immunosuppression medications targeted to our specific cell therapy clinical applications within the Cell Pouch platform.

• Sernova has acquired all the patented technology and knowhow for a cellular local immune protection technology (Conformal Coating Technology)

o an exclusive worldwide license agreement with the University of Miami was signed, broadening this technology scope.

o Sernova intends on bringing the Cell Pouch platform technologies, which includes conformally coated therapeutic cell technology, to the clinic first for our diabetes donor and stem cell programs with the goal to improve current cell therapy treatment options.

• Sernova also entered into a collaboration agreement with AgeX Therapeutics to utilize their UniverCyte™ technology. The objective is to generate transplantable genetically engineered stem cells that are immune protected to treat diseases for use in Sernova’s Cell Pouch.

Sernova is in active collaborations with leading global pharmaceutical companies for multiple cell therapy clinical applications in combination with Sernova’s cell therapy therapeutic platform and technologies. The goal of these collaborations is to initiate co-development and/or licensing agreements, as well as the potential ability to market and distribute our regenerative medicine therapeutics worldwide.

Dr. Toleikis will participate in the first of a series of conference calls for shareholders to provide corporate updates and answer questions at 11:00 am (EDT) on March 18, 2021. A presentation will be made available on Sernova’s website before the call. All questions to Dr. Toleikis can be submitted to info@sernova.com prior to the call. To participate in this live conference call, please visit:

Meeting link: https://sernovacorp.my.webex.com/sernovacorp.my/j.php?MTID=md016888548d385cd4fea3878b73a9b5d Meeting number: 182 490 4245 Password: SVAMarch2021 (78262724 from phones and video systems)

Join by phone +1-416-915-6528 CANADA TOLL +1-415-655-0001 US TOLL Access code: 182 490 4245 (Global call-in numbers available upon request)

Following the conference call a recording will be available at www.sernova.com

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information, please contact: Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - March 01, 2021 1 March, 2021

SERNOVA ANNOUNCES CLOSING OF C$23 MILLION BOUGHT DEAL FINANCING INCLUDING FULL EXERCISE OF OVER-ALLOTMENT OPTION

LONDON, ONTARIO – March 1, 2021 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (Frankfurt/Xetra: PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that it has closed its previously announced bought deal financing of 16,700,000 units of the Company (the “Units”) at a price of C$1.20 per Unit (the “Issue Price”), and the exercise in full of the Over-Allotment Option of 2,505,000 Units at the Issue Price, for aggregate gross proceeds to the Company of approximately C$23,046,000 (the “Offering”).

Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share (as “Warrant Share”) at an exercise price of C$1.70 (the “Exercise Price”) until March 1, 2023. The expiry date of the Warrants may be accelerated by the Company if the daily volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the “Exchange”) is greater than C$3.05 for the preceding ten (10) consecutive trading days, at which time the Company may accelerate the expiry date of the Warrants by providing notice to the holders of Warrants or issuing a news release announcing such acceleration, whereupon the Warrants will expire not less than 30 days after the date of such notice or news release.

The Offering was conducted on a “bought deal” basis, led by Canaccord Genuity Corp. and Leede Jones Gable Inc. as co-lead underwriters (together, the “Underwriters). As consideration for their services in connection with the Offering, the Company paid to the Underwriters: (i) a cash commission of $1,452,981; (ii) a corporate finance fee of 384,100 Units; and (iii) 1,210,818 compensation options (the “Compensation Options”), where each Compensation Option entitles the holder thereof to purchase one Unit (a “Compensation Unit”) at the Issue Price until March 1, 2023. Each Compensation Unit is comprised of one Share and one Warrant exercisable into a Warrant Share at the Exercise Price.

The net proceeds of the Offering will be used to advance the Company’s clinical development programs, including its US Phase I/II Cell Pouch clinical trial in insulin-dependent diabetes, expand the Company’s research and development programs, including its local immune protection technologies for the Cell Pouch, as well as for working capital and general corporate purposes.

The Offering was completed (i) by way of a short form prospectus filed in each of the provinces of Canada, other than Quebec, pursuant to National Instrument 44-101 – Short Form Prospectus Distributions, (ii) on a private placement basis in the United States pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and applicable U.S. state securities laws, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company’s securities under domestic or foreign securities laws. The securities referred to in this press release have not been, nor will they be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.

About Sernova Corp.

Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray

Sernova Corp

T: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward-Looking Information

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Sernova’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the intended use of proceeds by the Company. Forward-looking information is based on reasonable assumptions that have been made by Sernova at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Examples of such risk factors include: credit; market (including equity, foreign exchange and interest rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful development of its product candidates, and strategic plans and to attract, develop and retain key executives; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's information technology; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations governing the Company’s business; dependence on key suppliers; granting of permits and licenses; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; as well as those risk factors disclosed under the heading “Risk Factors” in the Company’s Annual Information Form (dated February 8, 2021) for the year ended October 31, 2020, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.

Press Release Communiqué de presse - February 25, 2021 25 February, 2021

Sernova Corp. Selected for the TSX Venture Stock Exchange’s 2021 Venture 50 List of Top Performing Listed Companies

February 25, 2021 9:00 a.m. EST

LONDON, ONTARIO - February 25, 2021 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (Frankfurt/Xetra:PSH), a clinical-stage company and leader in regenerative medicine therapeutics is pleased to announce that the TSX Venture Stock Exchange (TSX Venture) has recognized Sernova as a 2021 Venture 50 company, showcasing the top 50 performing listed companies.

“We are honoured to be chosen for the 2021 Venture 50 list and to be included amongst this distinguished group of industry leaders. We share this honour with our institutional and retail investors who are supporting our continued success and growth,” said Dr. Philip Toleikis, President and CEO of Sernova Corp. “This recognition is another validation of Sernova’s ongoing therapeutic advancements and builds upon what will be another very strong year as we continue to grow the company and build further shareholder value.”

The Venture 50 are the top ten companies listed on TSX Venture Exchange in each of five major industry sectors – mining, energy & energy services, clean technology & life sciences, diversified industries and technology – based on a ranking formula with equal weighting given to market cap growth, trading volume amount and share price appreciation. All data was as of December 31, 2020.

ABOUT SERNOVA’S CELL POUCH SYSTEM

The Cell Pouch system including the Cell Pouch, which is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The Cell Pouch along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans. In early assessments of its ongoing Phase I/II clinical trial, Sernova has shown presence of blood levels of c-peptide both during glucose tolerance tests as well as under fasting conditions. Clinical testing is ongoing at the University of Chicago.

ABOUT SERNOVA CORP

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Dominic Gray

Sernova Corp

Tel: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

FORWARD-LOOKING INFORMATION

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - February 24, 2021 24 February, 2021

Sernova Obtains Final Prospectus Receipt for $20 Million Bought Deal

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

LONDON, ONTARIO – February 24, 2021 – Sernova Corp. ("Sernova" or the "Company") (TSX-V: SVA) (OTCQB: SEOVF) (Frankfurt/Xetra:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce it has received a receipt for its final short form prospectus dated February 24, 2021 (the "Final Prospectus") in connection with its previously announced bought deal offering of 16,700,000 units of the Company (the "Units") at a price of C$1.20 per Unit for gross proceeds of approximately C$20,040,000 (the "Offering"). Canaccord Genuity Corp. and Leede Jones Gable Inc. are the co-lead underwriters (together, the "Underwriters") of the Offering.

The Company expects to close the Offering on or around March 1, 2021.

The Company has granted the Underwriters an option, exercisable in part or in whole at the Underwriter's sole discretion, at any time until 30 days following closing, to purchase up to that number of additional Units equal to 15% of the aggregate number of Units sold in the Offering.

The Final Prospectus was filed with the securities regulatory authorities in all provinces of Canada, except Quebec, and is available under the Company's SEDAR profile at www.sedar.com.

The securities referred to in this press release have not been, nor will they be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.

About Sernova Corp.

Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells, and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray

Sernova Corp

Tel: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward-Looking Information

This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Sernova's current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Offering, including the timing and ability of the Company to close the Offering, receipt of all regulatory and stock exchange approvals, the intended use of proceeds by the Company and the exercise of the Over-allotment Option by the Underwriters. Forward-looking information is based on reasonable assumptions that have been made by Sernova at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Examples of such risk factors include: the inability of the Company to close the Offering or to obtain all necessary Exchange and regulatory approvals; credit; market (including equity, foreign exchange and interest rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful development of its product candidates, and strategic plans and to attract, develop and retain key executives; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's information technology; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations governing the Company’s business; dependence on key suppliers; granting of permits and licenses; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; as well as those risk factors disclosed under the heading “Risk and Uncertainties” in the Company’s annual MD&A (dated February 1, 2021) for the years ended October 31, 2020 and 2019, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.

Press Release Communiqué de presse - February 18, 2021 18 February, 2021

Sernova Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System™ Clinical Trial and Recommendation for Protocol Continuation

Ongoing Safety of Sernova's Clinical Trial Confirmed

February 18, 2021 9:00 a.m. EST

LONDON, ONTARIO – February 18, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical- stage company and leader in regenerative medicine therapeutics, is pleased to announce that the clinical trial independent Data Safety Monitoring Board ("DSMB") has completed the second planned annual review of the ongoing Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation Phase I/II clinical trial in patients with severe hypoglycemia unawareness and inability to produce their own insulin. The DSMB recommended that the Phase I/II clinical study should continue according to the study protocol and any related amendments. In their assessment, the DSMB did not raise any concerns regarding patient safety.

"We are pleased with the second annual independent DSMB review of our Phase I/II clinical trial," said Dr. Philip Toleikis, President & CEO Sernova Corp. "We thank the DSMB for its diligence, guidance and support as Sernova continues progressing the clinical trial."

The DSMB is an independent group of clinical research experts who review the accumulated data to permit a thorough evaluation of patient safety and to ensure the integrity of the study's data and progress towards completion.

ABOUT SERNOVA'S CLINICAL TRIAL

Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial to assess the safety and tolerability of islet transplantation into the company's patented Cell Pouch in diabetic subjects with hypoglycemia unawareness and an inability to produce their own insulin. The secondary objective is to assess efficacy through a series of defined measures. Eligible subjects are implanted with Cell Pouches. Following development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch. A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow-up. Following this period, eligible patients may be administered a single dose of islets through the portal vein. Patients will be then further followed for one year to assess longer-term safety and efficacy. This study is supported in part by funding from JDRF, the leading global organization funding type 1 diabetes (T1D) research.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.

ABOUT SERNOVA'S CELL POUCH SYSTEM

The Cell Pouch system including the Cell Pouch, which is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long- term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The Cell Pouch along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin- producing cells in humans. In early assessments of its ongoing Phase I/II clinical trial, Sernova has shown presence of blood levels of c-peptide both during glucose tolerance tests as well as under fasting conditions. Clinical testing is ongoing at the University of Chicago.

ABOUT SERNOVA CORP

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Dominic Gray

Sernova Corp

Tel: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

FORWARD-LOOKING INFORMATION

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova's management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - February 04, 2021 4 February, 2021

Sernova Shares Accepted for Trading on the Electronic Trading Platform Xetra in Germany

February 4, 2021 9:00 a.m. EST

LONDON, ONTARIO – February 4, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce the start of trading of Sernova shares on Xetra, the electronic trading system of Deutsche Börse AG in Germany (German Securities Identification Number (WKN): A0LBCR, International Securities Identification Number (ISIN): CA81732W1041, German Ticker-Symbol: PSH).

Xetra is an electronic trading platform operated by the Frankfurt Stock Exchange. It offers trading in stocks, funds, bonds, warrants, and commodities contracts. Launched in 1997, the majority of stock market transactions in Germany are through the Xetra trading venue: approximately 90 percent of all trading in shares across all German exchanges is now conducted through Xetra making it the largest of Germany’s stock exchanges. Over 200 trading participants from 16 European countries, United Arab Emirates and Hong Kong are connected via Xetra servers.

Xetra is the first and primary choice for institutional investors with its significantly higher liquidity and narrower price spreads. Given the high turnover (liquidity) on the Xetra trading venue, orders for securities are executed swiftly and at prices in line with the market. Moreover, this principle is supported by Designated Sponsors who post binding purchase and selling prices (quotes) continuously and thus ensure additional liquidity and fair prices, making it the first choice for institutional investors. mwb Wertpapierhandelsbank AG will act as Designated Sponsor (active market maker) to handle the trading of Sernova’s shares on Xetra with immediate effect and therefore contribute to increased trading liquidity.

mwb fairtrade Wertpapierhandelsbank AG (www.mwbfairtrade.com) is a securities service provider licensed by the German Federal Financial Supervisory Authority (BaFin) with branches near Munich, Hamburg, Hanover, Frankfurt as well as Berlin. Founded in 1993 and active in two business divisions: Securities Trading and Corporates & Markets, mwb manages approximately 40,000 order books for German and international securities as well as 89 Designated Sponsors mandates making mwb one of the largest order book managers in Germany.

“mwb has developed in-depth knowledge on enabling Xetra trading for overseas companies. We are happy to support Sernova with the rollout of their exciting equity story and look forward to enhance Euro-based trading possibilities for their institutional and retail investor base in Europe,” said Sascha Guenon, Head of Designated Sponsoring and Corporate Broking at mwb.

“We are experiencing a significant increase of interest from institutional investors in Europe, especially in German-speaking countries, and want to provide them with a more efficient way to trade our shares," commented Dr. Philip Toleikis, President and CEO of Sernova. "This is an important step to increase the percentage of long-term oriented institutional investors within our group of shareholders who understand the potential of our innovative platform technologies in the regenerative medicine field as well as the valuation gap with our competitors. mwb has a strong network of biotech investors and we are looking forward to presenting the potential of Sernova’s regenerative medicine platform to them.”

ABOUT SERNOVA

Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Dominic Gray

Sernova Corp

Tel: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

FORWARD-LOOKING INFORMATION

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - February 04, 2021 4 February, 2021

Sernova Upsizes Previously Announced Bought Deal Public Offering to C$20 Million

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES LONDON, ONTARIO – February 4, 2021 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF)(FSE: PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that it has entered into an amendment (the “Amendment”) to its previously announced agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc., as co-lead underwriters (together, the “Underwriters”), pursuant to which the Underwriters have agreed to increase the size of the previously announced bought deal financing. Pursuant to the Amendment, the Underwriters have agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 16,700,000 units of the Company (the “Units”) at a price of C$1.20 per Unit for gross proceeds to the Company of approximately C$20,040,000 (the “Offering”).

The Company has granted the Underwriters an option (the “Over-allotment Option”), exercisable in part or in whole at the Underwriters’ discretion, at any time until thirty (30) days following the Closing Date, to purchase up to the number of additional Units equal to 15% of the aggregate number of Units sold in the Offering to cover over-allotments, if any.

All other terms of the Offering remain consistent with the Company’s previous announcement on February 3, 2021.

The net proceeds of the Offering will be used to advance the Company’s clinical development program, including its US Phase I/II Cell Pouch clinical trial, expand Sernova’s research and development programs, including our local immune protection technologies for the Cell Pouch, as well as for working capital and general corporate purposes.

The Offering will be completed (i) by way of a short form prospectus to be filed in those provinces of Canada other than Quebec as the Underwriters and the Company may designate pursuant to National Instrument 44- 101 – Short Form Prospectus Distributions, (ii) on a private placement basis in the United States pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and applicable U.S. state securities laws, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company’s securities under domestic or foreign securities laws.

The Offering is expected to close on February 24, 2021 and is subject to certain customary conditions including the approval of the TSX Venture Exchange and applicable securities regulatory authorities.

The securities referred to in this press release have not been, nor will they be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.

About Sernova Corp.

Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray

Sernova Corp

T: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward-Looking Information

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Sernova’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Offering, including the timing and ability of the Company to close the Offering, receipt of all regulatory and stock exchange approvals, the intended use of proceeds by the Company and the exercise of the Over-allotment Option by the Underwriters. Forward-looking information is based on reasonable assumptions that have been made by Sernova at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Examples of such risk factors include: the inability of the Company to close the Offering or to obtain all necessary Exchange and regulatory approvals; credit; market (including equity, foreign exchange and interest rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful development of its product candidates, and strategic plans and to attract, develop and retain key executives; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's information technology; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations governing the Company’s business; dependence on key suppliers; granting of permits and licenses; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; as well as those risk factors disclosed under the heading “Risk and Uncertainties” in the Company’s annual MD&A (dated February 1, 2021) for the years ended October 31, 2020 and 2019, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.

Privacy PolicyPolitique de confidentialité